-
Promising Breakthrough: Johnson & Johnson Reports Strong Data for Pasritamig in Prostate Cancer Treatment
NYSE: $JNJ A New Frontier in Prostate Cancer Research In a significant development for oncology, Johnson & Johnson has released positive results from its clinical trials concerning an investigational immunotherapy drug known as pasritamig. The findings, which focus on its application in treating prostate-specific antigen (PSA) levels, offer a glimmer of hope for patients facing…
-
A Breakthrough in Lung Cancer Treatment: FDA Approves Rybrevant + Lazertinib Combination
NYSE: $JNJ A New Frontier in Targeted Therapy In a significant development for oncology, Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved Rybrevant (amivantamab-vmjw) in combination with lazertinib. This treatment is specifically indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung…
-
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren’s disease that reveal insights on importance of symptom improvements most valued by patients
New patient experience data to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights complement Phase 2 study results demonstrating a 50% increase in saliva productionb in more… Source: Read More
-
A New Frontier in Oncology: Johnson & Johnson Reports Promising Results for Advanced Prostate Cancer
NYSE: $JNJ A Breakthrough in Prostate Cancer Research Johnson & Johnson has recently unveiled highly encouraging data regarding its novel therapeutic candidate, JNJ-6420 (often studied in the context of RIPTAC technology). In clinical trials targeting advanced prostate cancer, the drug demonstrated a remarkable 75% tumor response rate, marking a significant milestone for patients facing limited…
-
A Medical Milestone: FDA Approves First-Ever Treatment for Warm Autoimmune Hemolytic Anemia
NYSE: $JNJ A Breakthrough for Patients In a significant milestone for hematology and immunology, the FDA has officially approved Imaavy (nipocalimab-aahu). This approval marks a historical turning point as it is the first-ever treatment specifically indicated for adults with warm autoimmune hemolytic anemia (wAIHA). Understanding Warm Autoimmune Hemolytic Anemia (wAIHA) Warm autoimmune hemolytic anemia is…